Upcoming Events and meetings
The 5th Complement-based Drug Development Summit returns to unite a community dedicated to maximizing complement-targeting in the pan-disease setting.
The Complement-based Drug Development Summit is comprehensively addressing the industry’s key challenges of understanding the intricacies of complement pathways to accelerate translation and clinical validation of novel complement inhibitors!
Join scientists, clinicians, allied health professionals, and trainees from across the globe at the Toronto Complement Conference 2021. This conference will provide participants with the opportunity to learn about exciting advances in the field of complement, network with world class experts, and engage in stimulating discussions.
Talks will cover a wide range of topics within the realm of complement-mediated diseases, with particular highlights including hot topics in complement, haematology, and paediatrics. We are proud to present an outstanding group of international experts as speakers, and invite you to actively participate in the scientific program via submission of your abstract(s).
This event will be held entirely virtually over Zoom.
This international meeting will cover state of the art lectures on complement in health and disease and emphasizes will be given on the translational aspects. Renowned international speakers will cover exciting and recent newest developments of complement therapeutics.
- Homeotic Complement
- Inflammatory Complement
- Complement Receptors and Intracellular Complement
- Association of Complement and Complement Activation Products in Human Diseases
- New Developments of Complement in Health and Disease
- Translational Complement
- Complement Diagnostics and Standardization
- Complement Therapeutics on the Way to the Clinics
The Frontiers Meeting 2021 is an International Society of Nephrology (ISN) event hosted by the Mario Negri Institute for Pharmacological Research.
The 2021 Frontiers Meeting will focus on the two prototypical complement-mediated kidney diseases: atypical hemolytic uremic syndrome (aHUS) and C3 Glomerulopathies /Membranoproliferative Glomerulonephritis (C3G/MPGN), both very rare and severe diseases. aHUS is an ultra-rare disease with an estimated prevalence of 1/100,000, while primary C3G/MPGN has an estimated prevalence of 16/100,000.
Next EMCHD is postponed to 2022 – Tentative plan is to hold conference on August 25-29, 2022 at the same venue in Bern.
The meeting will provide the complement community with a great opportunity to share and discuss their clinical as well as laboratory results with colleagues and hear about new findings within our fields. This will be complemented by a teaching day in a very friendly and welcoming atmosphere in the heart of Switzerland.